Dayvigo and Opioids Interaction: What Women Need to Know About Lemborexant With Oxycodone, Hydrocodone, or Tramadol

The Core Risk: Why This Combination Matters for Women

Lemborexant (Dayvigo) and opioids depress the central nervous system through entirely different but additive mechanisms. When you take both, the combined sedation and respiratory slowdown can be greater than either drug alone, and for women in particular, that additive effect is not always predictable.

Insomnia affects women at roughly twice the rate seen in men across most age groups, and chronic pain conditions that lead to opioid prescriptions, including fibromyalgia, endometriosis-related pelvic pain, and postoperative pain, are also disproportionately diagnosed in women. That means the real-world likelihood of a woman being prescribed both a sleep agent and an opioid analgesic is higher than population-level statistics suggest.

The FDA prescribing information for lemborexant explicitly states that concomitant use with other CNS depressants, including opioids, increases the risk of CNS depression. The label advises that the dose of lemborexant should be reduced or that the combination should be avoided altogether.

A 2019 analysis published in JAMA Internal Medicine found that co-prescription of CNS-depressant sleep agents with opioids was associated with a significantly elevated risk of overdose death, underscoring why this is not a theoretical concern.

Mechanism: How Lemborexant and Opioids Interact at the Molecular Level

Pharmacodynamic Combination

Lemborexant works by blocking orexin receptors (OX1R and OX2R), the wake-promoting neuropeptide system in the hypothalamus. It does not act on GABA receptors, which sets it apart from benzodiazepines and Z-drugs. Opioids, by contrast, act primarily on mu-opioid receptors throughout the brain and brainstem, directly suppressing respiratory drive and arousal.

Because these two drug classes hit different receptor systems, you might assume the interaction would be limited. It is not. The net physiological output, sedation plus reduced ventilatory response to hypercapnia, is additive regardless of receptor mechanism. The brainstem respiratory centers that opioids suppress are also modulated by arousal signals from orexin neurons, so blocking orexin with lemborexant removes a compensatory wake signal at the very moment opioids are blunting respiratory drive.

CYP3A4 and the Tramadol Wrinkle

All three opioids in question have some pharmacokinetic relevance here, but tramadol adds a metabolic layer.

Lemborexant is metabolized primarily by CYP3A4, and its plasma concentrations rise substantially when a CYP3A4 inhibitor is co-administered. Tramadol is also a CYP3A4 substrate, and at higher doses it can weakly inhibit CYP3A4 activity. In practice this interaction is unlikely to cause clinically dramatic CYP-mediated elevation of lemborexant levels on its own, but it adds to the overall pharmacokinetic uncertainty.

Oxycodone and hydrocodone are metabolized predominantly by CYP3A4 and CYP2D6. Neither meaningfully inhibits the enzymes that process lemborexant, so the oxycodone and hydrocodone interactions with lemborexant are predominantly pharmacodynamic rather than pharmacokinetic. That matters clinically: pharmacodynamic interactions are harder to dose-adjust around because there is no straightforward plasma-level target to monitor.

Sex-Specific Pharmacokinetics

Women generally have lower lean body mass, higher percentage body fat, and different CYP enzyme activity compared with men. CYP3A4 activity is on average higher in women than in men, which means women may clear lemborexant somewhat faster at baseline. However, hormonal fluctuations during the menstrual cycle and the estrogen decline of perimenopause alter CYP3A4 expression, making drug exposure less predictable across a woman's lifespan.

A pharmacokinetic review in Clinical Pharmacology and Therapeutics documented that women show significantly higher opioid-induced respiratory depression at equivalent plasma concentrations compared with men, likely due to differences in mu-opioid receptor density and sensitivity. This sex difference means the additive CNS depression from combining lemborexant with an opioid may land harder in a woman than the clinical trial data, derived mostly from mixed-sex or male-skewed populations, would predict.

Evidence gap note: The phase 3 trials that supported lemborexant's approval (SUNRISE 1 and SUNRISE 2) were approximately 60% female, which is better than most CNS drug trials, but neither trial enrolled patients on chronic opioids as a pre-specified subgroup. Direct interaction data in women on opioids does not exist. The risk assessment below is extrapolated from mechanism, pharmacokinetics, and CNS-depressant class data.

Severity Rating and Clinical Classification

The interaction between lemborexant and opioids is classified as major in standard drug interaction databases, including Lexicomp and Micromedex. Major-severity ratings indicate that the combination may be life-threatening or require a medical intervention to prevent serious harm.

The FDA Drug Safety Communication on combined opioid and CNS-depressant prescribing issued in 2016 specifically required black box warning updates across all opioid labels and many CNS-depressant labels, noting that the combination of opioids with sleep medications was linked to cases of profound sedation, respiratory depression, coma, and death.

Life-Stage Considerations Across the Female Lifespan

Different stages of a woman's reproductive and hormonal life change the clinical calculus for this combination in ways that standard drug references do not address.

Reproductive Years (Ages 18-40)

Women in their reproductive years who use opioids for conditions like endometriosis, interstitial cystitis, or chronic migraine, and who also have comorbid insomnia, face a direct risk from this combination. If you are in this group and your clinician has prescribed both, ask specifically whether a non-pharmacological insomnia intervention such as CBT-I has been trialed first, and whether the opioid can be scheduled so peak plasma levels do not coincide with lemborexant dosing.

Oral contraceptive pills are moderate CYP3A4 inducers. If you take combined hormonal contraception, your lemborexant clearance may be modestly increased, slightly lowering plasma concentrations. This does not eliminate the interaction risk, but it is a variable your prescriber should know about.

Trying to Conceive and Pregnancy

Lemborexant is contraindicated in pregnancy. The FDA label states that there are no adequate human data on the use of lemborexant in pregnant women to evaluate for drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies showed increased embryofetal death and reduced fetal weight at doses producing plasma exposures below the human therapeutic range.

Opioids taken in pregnancy are associated with neonatal opioid withdrawal syndrome and, with chronic use, with congenital heart defects in some registry studies. Combining lemborexant with an opioid while pregnant is doubly concerning, and both drugs should be reconsidered with your OB or MFM specialist.

If you are of reproductive age and using lemborexant, reliable contraception is strongly recommended. Discuss this with your prescriber.

Postpartum and Lactation

Lemborexant's transfer into breast milk has not been studied in humans. The FDA label advises that the developmental and health benefits of breastfeeding should be considered along with the mother's need for lemborexant and any potential adverse effects on the infant from the drug or the underlying condition. Given zero human lactation data, most clinicians recommend avoiding lemborexant while breastfeeding. Opioids including hydrocodone and oxycodone do transfer into breast milk and can cause neonatal sedation and respiratory depression. Adding a CNS-depressant sleep agent creates an unacceptable stacking risk for an infant.

Postpartum insomnia is extremely common and often severe. CBT-I remains the preferred first-line treatment throughout the postpartum period, and it is also the recommended first-line approach per ACOG's guidance on sleep in pregnancy and postpartum.

Perimenopause

This is the life stage where the Dayvigo-plus-opioid combination is most likely to go clinically unnoticed. Perimenopausal women have dramatically higher rates of insomnia, driven by vasomotor symptoms and progesterone decline, and they also disproportionately carry diagnoses of chronic musculoskeletal pain, migraine, and conditions that generate opioid prescriptions.

A 2020 study in Menopause reported that up to 61% of perimenopausal women report significant sleep disturbance. Declining estrogen also alters opioid receptor sensitivity, and progesterone itself has respiratory stimulant properties; its loss in late perimenopause may reduce a woman's baseline protection against opioid-induced respiratory depression.

If you are perimenopausal and taking an opioid for pain, your prescriber should know before initiating lemborexant. Menopause hormone therapy (MHT) addressing the root cause of vasomotor-related insomnia may be a better path, potentially reducing the need for a dedicated sleep agent altogether.

Post-Menopause

Post-menopausal women taking opioids for osteoarthritis, vertebral fracture pain, or other chronic conditions have lower progesterone to buffer respiratory drive and may show greater opioid sensitivity at a given dose. The absence of cyclical hormone fluctuation makes CYP3A4 activity relatively stable, which is one less variable, but the baseline respiratory vulnerability is higher. Fall risk from sedation is a material concern: both lemborexant and opioids independently increase fall and fracture risk, and postmenopausal women are already at elevated baseline fracture risk.

Who This Combination Is Not Right For

The following women should not take lemborexant and an opioid together without a formal specialist review and documented risk-benefit discussion:

• Women with obstructive sleep apnea (OSA is markedly worsened by both drug classes)
• Women on chronic daily opioid therapy (>90 morphine milligram equivalents per day)
• Women in the first trimester of pregnancy or actively trying to conceive
• Women who are breastfeeding
• Women with COPD or other causes of reduced baseline respiratory reserve
• Women taking additional CNS depressants (benzodiazepines, muscle relaxants, gabapentinoids, antihistamines)
• Women who consume alcohol regularly, since alcohol is itself a CYP3A4 inhibitor and CNS depressant

When the Combination May Be Considered With Monitoring

In specific clinical scenarios, a prescriber may decide the benefit of lemborexant outweighs the risk, even with concurrent opioid use. These are the conditions under which that decision might be defensible:

Lowest Effective Dose of Both Agents

The FDA label for lemborexant recommends starting at 5 mg. If a CNS-depressant combination is unavoidable, using the minimum effective dose of lemborexant (5 mg, not 10 mg) reduces the pharmacodynamic contribution of the sleep agent. Similarly, the opioid should be at the lowest dose and shortest duration consistent with the pain indication.

Avoiding Peak-Concentration Overlap

Lemborexant reaches peak plasma concentration (Tmax) at approximately 1 to 3 hours after administration. Short-acting opioids like oxycodone immediate-release peak at 1 to 2 hours. Scheduling opioid doses so that peak occurs several hours before bedtime and lemborexant dosing does not eliminate the interaction but may reduce the severity of simultaneous CNS depression during sleep.

Active Monitoring Parameters

If the combination proceeds, these monitoring parameters should be in place:

• Pulse oximetry spot-checks, especially in the first week
• A bed partner or household member instructed on signs of respiratory depression
• Naloxone co-prescription (which many states now mandate when opioids are prescribed alongside CNS depressants)
• Reassessment at every prescription refill, with documented sedation scale scoring
• Discussion of OSA screening if not already performed

Pregnancy and Lactation Safety Summary

Pregnancy: Lemborexant is not recommended in pregnancy. No adequate human data exist. Animal reproductive toxicity data show embryofetal harm at sub-therapeutic exposures. Opioids carry their own fetal risks including neonatal opioid withdrawal syndrome. The combination in pregnancy is not supported by any evidence and should be avoided.

Lactation: Human lactation data for lemborexant are absent. Given the drug's CNS activity and the infant's immature blood-brain barrier, transfer of even small amounts could cause neonatal sedation. Breastfeeding women who need pharmacological sleep support should discuss alternatives with their clinician. CBT-I is safe and has demonstrated efficacy in postpartum insomnia in randomized trials.

Contraception: Women of reproductive potential taking lemborexant should use reliable contraception, given the absence of human fetal safety data. If you are on hormonal contraception, inform your prescriber, as it may modestly alter lemborexant pharmacokinetics via CYP3A4 induction.

Opioid-Specific Notes: Oxycodone vs. Hydrocodone vs. Tramadol

All three opioids carry the same pharmacodynamic warning when combined with lemborexant, but there are drug-specific nuances worth knowing.

Oxycodone: Primarily a CYP3A4 and CYP2D6 substrate. Extended-release formulations (OxyContin) produce prolonged plasma levels that overlap with an entire night's lemborexant exposure rather than just a brief peak window. The additive respiratory depression risk is sustained through the sleep period. The oxycodone prescribing information carries a black box warning against use with other CNS depressants.

Hydrocodone: Similar CYP3A4/CYP2D6 metabolism. Most formulations are combined with acetaminophen (Vicodin, Norco), which adds hepatic concerns at high doses. The CNS-depressant interaction risk with lemborexant is equivalent to oxycodone.

Tramadol: The most complex of the three. Tramadol is both a weak mu-opioid agonist and a serotonin-norepinephrine reuptake inhibitor. It is metabolized by CYP3A4 and CYP2D6 to O-desmethyltramadol, the active mu-agonist metabolite. The serotonergic activity of tramadol adds a serotonin syndrome risk if other serotonergic agents are also in the picture, though lemborexant itself is not serotonergic. Women who are CYP2D6 poor metabolizers (approximately 7% of White women and lower rates in East Asian women) accumulate less active metabolite and may experience less analgesia but are also somewhat less exposed to respiratory depression from tramadol specifically. Tramadol's CNS-depressant label warning parallels those for full mu-agonist opioids.

What to Tell Your Clinician Before Starting Either Drug

If you are already taking an opioid and your clinician recommends lemborexant for insomnia, provide this information at the visit:

1. The name, dose, and schedule of your opioid, including whether it is immediate- or extended-release
2. Any other sleep aids, anxiolytics, muscle relaxants, or antihistamines you take, including over-the-counter options
3. Whether you have been told you snore heavily or have sleep apnea
4. Your alcohol use pattern
5. Whether you are pregnant, breastfeeding, or planning a pregnancy
6. All hormonal medications including contraceptives, because they alter CYP3A4 activity
7. Any history of respiratory disease, liver disease, or prior overdose

Your prescriber may want to try CBT-I first. The American College of Obstetricians and Gynecologists and The Menopause Society both list CBT-I as the preferred first-line treatment for insomnia before any pharmacological agent. If you have already tried CBT-I and it has not worked, document that in your medical record. It strengthens the clinical justification for lemborexant and helps establish that the prescriber considered the lowest-risk path first.